Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Type of study
Language
Year range
1.
Indian J Med Microbiol ; 2003 Apr-Jun; 21(2): 133-4
Article in English | IMSEAR | ID: sea-53632

ABSTRACT

Injection abscess is an iatrogenic infection occurring as an isolated case or as cluster outbreak. These infections occur due to contaminated injectables or lapse in sterilisation protocol. While pathogens such as Pseudomonas, Klebsiella, E. coli, and S. aureus are the usual causative agents, unusual organisms such as mycobacteria, particularly the rapidly growing non-tuberculous mycobacteria (NTM) may cause the abscess. The chances of overlooking these organisms is high unless an acid fast bacilli (AFB) smear and culture is done on all aspirated pus specimens. We report a case of a three year old child who presented with a gluteal abscess following an intramuscular infection with an unknown preparation.

2.
Article in English | IMSEAR | ID: sea-23874

ABSTRACT

Metallo beta-lactamase (MBL) producing Pseudomonas aeruginosa is an emerging threat and a cause of concern for the physicians treating such infections. The present study was undertaken to know the resistance pattern of P. aeruginosa to beta-lactamase inhibitors and carbapenems, and to detect the presence of MBL among resistant isolates to both groups of antibiotics. Between June-November 2001, 50 P. aeruginosa isolates from clinical specimens were tested for susceptibility to beta-lactamase inhibitors and carbapenems by Kirby-Bauer disc diffusion method. Isolates resistant to both groups of antibiotics were screened for the presence of MBLs by disc diffusion method using 2-mercaptoethanol. Of the 50 isolates, 6 (12%) were resistant to both beta-lactamase inhibitors and carbapenems. All 6 isolates were MBL producers were resistant to all the antibiotics tested. Resistance to piperacillin-tazobactam, cefoperazone-sulbactam and ticarcillin-clavulanic acid was 12, 20 and 36 per cent respectively. Resistance of 12 per cent each was noted to imipenem and meropenem respectively. This is to the best of our knowledge the first report of MBL producing P. aeruginosa from India and suggests the need for early detection, notification and control of spread.


Subject(s)
Anti-Bacterial Agents/pharmacology , Carbapenems/pharmacology , Drug Resistance, Bacterial , Enzyme Inhibitors/metabolism , Hospitalization , Humans , India , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , beta-Lactamases/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL